DE69833464D1 - Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate - Google Patents

Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate

Info

Publication number: DE69833464D1
Authority: DE; Germany
Prior art keywords: bpyridazine; pyrazolo1; diaryl; derivatives; pharmaceutical composition
Prior art date: 1997-09-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69833464T

Other languages

English (en)

Other versions

DE69833464T2 (de

Inventor

John Beswick

Baxter Campell

Neil Mathews

Alan Naylor

Charanjit Bountra

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-05

Filing date

1998-09-03

Publication date

2006-04-20

1997-09-05 Priority claimed from GBGB9718792.6A external-priority patent/GB9718792D0/en

1997-12-23 Priority claimed from GBGB9727116.7A external-priority patent/GB9727116D0/en

1998-09-03 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2006-04-20 Application granted granted Critical

2006-04-20 Publication of DE69833464D1 publication Critical patent/DE69833464D1/de

2006-08-24 Publication of DE69833464T2 publication Critical patent/DE69833464T2/de

2018-09-04 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Immunology (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Psychology (AREA)

DE69833464T 1997-09-05 1998-09-03 Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate Expired - Lifetime DE69833464T2 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB9718792.6A GB9718792D0 (en)	1997-09-05	1997-09-05	Chemical compounds
GB9718792		1997-09-05
GB9727116		1997-12-23
GBGB9727116.7A GB9727116D0 (en)	1997-12-23	1997-12-23	Chemical compounds

Publications (2)

Publication Number	Publication Date
DE69833464D1 true DE69833464D1 (de)	2006-04-20
DE69833464T2 DE69833464T2 (de)	2006-08-24

Family

ID=26312181

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DE69816651T Expired - Lifetime DE69816651T2 (de)	1997-09-05	1998-09-03	2,3-diaryl-pyrazolo[1,5-b]pyridazin derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren
DE69827419T Expired - Lifetime DE69827419T2 (de)	1997-09-05	1998-09-03	Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-Pyrazolo[1,5-b]Pyridazin Derivate
DE69833464T Expired - Lifetime DE69833464T2 (de)	1997-09-05	1998-09-03	Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DE69816651T Expired - Lifetime DE69816651T2 (de)	1997-09-05	1998-09-03	2,3-diaryl-pyrazolo[1,5-b]pyridazin derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren
DE69827419T Expired - Lifetime DE69827419T2 (de)	1997-09-05	1998-09-03	Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-Pyrazolo[1,5-b]Pyridazin Derivate

Country Status (28)

Country	Link
US (4)	US6451794B1 (de)
EP (3)	EP1369421B1 (de)
KR (1)	KR100382619B1 (de)
CN (1)	CN1155600C (de)
AP (1)	AP1354A (de)
AT (3)	ATE281458T1 (de)
AU (1)	AU744997B2 (de)
BG (1)	BG64420B1 (de)
BR (1)	BR9812046A (de)
CA (1)	CA2303152A1 (de)
DE (3)	DE69816651T2 (de)
DK (1)	DK1032575T3 (de)
EA (1)	EA002775B1 (de)
EE (1)	EE04617B1 (de)
ES (3)	ES2203985T3 (de)
HR (1)	HRP20000122B1 (de)
HU (1)	HUP0003644A3 (de)
IL (1)	IL134688A (de)
IS (1)	IS5389A (de)
NO (1)	NO315559B1 (de)
NZ (1)	NZ502985A (de)
PL (1)	PL194557B1 (de)
PT (1)	PT1032575E (de)
SK (1)	SK283922B6 (de)
TR (1)	TR200000595T2 (de)
TW (1)	TW570922B (de)
WO (1)	WO1999012930A1 (de)
YU (1)	YU11900A (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA002775B1 (ru)	1997-09-05	2002-08-29	Глаксо Груп Лимитед	ПРОИЗВОДНЫЕ 2,3-ДИАРИЛ-ПИРАЗОЛО[1,5-b]ПИРИДАЗИНОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ЦИКЛООКСИГЕНАЗЫ 2 (ЦОГ-2)
AU767464B2 (en)	1998-11-03	2003-11-13	Glaxo Group Limited	Pyrazolopyridine derivatives as selective COX-2 inhibitors
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1157025B1 (de)	1999-02-27	2004-03-10	Glaxo Group Limited	Pyrazolopyridine
US7172769B2 (en)	1999-12-08	2007-02-06	Pharmacia Corporation	Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
GB9929039D0 (en) *	1999-12-08	2000-02-02	Glaxo Group Ltd	Medicaments
GB9930358D0 (en) *	1999-12-22	2000-02-09	Glaxo Group Ltd	Process for the preparation of chemical compounds
RU2002119574A (ru)	1999-12-23	2004-01-10	Нитромед, Инк. (Us)	Нитрозированные и нитрозилированные ингибиторы циклооксигеназы-2, композиции на их основе и способы их применения
GB0002312D0 (en) *	2000-02-01	2000-03-22	Glaxo Group Ltd	Medicaments
PT1303265E (pt)	2000-07-20	2007-10-09	Lauras As	''utilização de inibidores da cox-2 como imuno-estimulantes, no tratamento do vih ou da sida''
PE20020506A1 (es) *	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0021494D0 (en) *	2000-09-01	2000-10-18	Glaxo Group Ltd	Chemical comkpounds
GB0025449D0 (en) *	2000-10-17	2000-11-29	Glaxo Group Ltd	Chemical compounds
DE60112330T2 (de)	2000-12-15	2006-04-13	Glaxo Group Ltd., Greenford	Pyrazolopyridinderivate
ATE301653T1 (de)	2000-12-15	2005-08-15	Glaxo Group Ltd	Pyrazolopyridine
JP2004529119A (ja)	2001-03-08	2004-09-24	スミスクラインビーチャムコーポレーション	ピラゾロピリジン誘導体
WO2002078700A1 (en)	2001-03-30	2002-10-10	Smithkline Beecham Corporation	Pyralopyridines, process for their preparation and use as therapteutic compounds
ES2266487T3 (es)	2001-04-10	2007-03-01	Smithkline Beecham Corporation	Compuestos de pirazolopirina antivirales.
US6756498B2 (en)	2001-04-27	2004-06-29	Smithkline Beecham Corporation	Process for the preparation of chemical compounds
DE60204452T2 (de)	2001-04-27	2005-12-15	Smithkline Beecham Corp.	Pyrazolo[1,5a]Pyridinderivate
GB0112802D0 (en) *	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0112810D0 (en) *	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
IL158667A0 (en)	2001-06-21	2004-05-12	Smithkline Beecham Corp	Imidazo [1,2-a] pyridine derivatives for the prophylaxis and treatment of herpes viral infections
AR038957A1 (es)	2001-08-15	2005-02-02	Pharmacia Corp	Terapia de combinacion para el tratamiento del cancer
ES2262893T3 (es)	2001-10-05	2006-12-01	Smithkline Beecham Corporation	Derivados de imidazo-piridina para su uso en el tratamiento de infeccion virica por herpes.
GB0124934D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124936D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124939D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124931D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124933D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124938D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124941D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124932D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
WO2003050120A1 (en)	2001-12-11	2003-06-19	Smithkline Beecham Corporation	Pyrazolo-pyridine derivatives as antiherpes agents
ES2262899T3 (es)	2001-12-17	2006-12-01	Smithkline Beecham Corporation	Derivados de pirazolopiridazina.
KR100686537B1 (ko)	2001-12-28	2007-02-27	씨제이 주식회사	사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체
KR100840907B1 (ko) *	2001-12-28	2008-06-24	씨제이제일제당 (주)	사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난바이피리디닐 유도체
MXPA04007838A (es)	2002-02-12	2004-10-15	Smithkline Beecham Corp	Derivados de nicotamida utiles como inhibidores p38.
GB0206200D0 (en) *	2002-03-15	2002-05-01	Glaxo Group Ltd	Pharmaceutical compositions
US7211598B2 (en)	2002-06-28	2007-05-01	Nitromed, Inc.	Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
GB0217757D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds
ATE325115T1 (de)	2002-08-19	2006-06-15	Glaxo Group Ltd	Pyrimidinderivate als selektive cox-2-inhibitoren
UY27939A1 (es)	2002-08-21	2004-03-31	Glaxo Group Ltd	Compuestos
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
EP1546148A1 (de)	2002-10-03	2005-06-29	SmithKline Beecham Corporation	Auf pyrazolopyridinderivaten basierende therapeutische verbindungen
US20040147581A1 (en) *	2002-11-18	2004-07-29	Pharmacia Corporation	Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
GB0227443D0 (en) *	2002-11-25	2002-12-31	Glaxo Group Ltd	Pyrimidine derivatives
ES2213485B1 (es) *	2003-02-13	2005-12-16	Almirall Prodesfarma, S.A.	Derivados de la 2-fenilpiran-4-ona.
ES2214129B1 (es) *	2003-02-13	2005-12-01	Almirall Prodesfarma, S.A.	3-fenilfuran-2-onas.
ES2214130B1 (es) *	2003-02-13	2005-12-01	Almirall Prodesfarma, S.A.	2-3'-bipiridinas.
US20040220155A1 (en) *	2003-03-28	2004-11-04	Pharmacia Corporation	Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
GB0308186D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308185D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308201D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
PL1745791T3 (pl)	2003-05-07	2013-11-29	Osteologix As	Leczenie chorób chrząstki/kości za pomocą rozpuszczalnych w wodzie soli strontu
US20050014729A1 (en) *	2003-07-16	2005-01-20	Pharmacia Corporation	Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
GB0318814D0 (en) *	2003-08-11	2003-09-10	Smithkline Beecham Corp	Novel compounds
GB0319037D0 (en) *	2003-08-13	2003-09-17	Glaxo Group Ltd	7-Azaindole Derivatives
US20050119262A1 (en) *	2003-08-21	2005-06-02	Pharmacia Corporation	Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005023189A2 (en) *	2003-09-03	2005-03-17	Pharmacia Corporation	Method of cox-2 selective inhibitor and nitric oxide-donating agent
GB0402143D0 (en) *	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
US20080051416A1 (en) *	2004-10-05	2008-02-28	Smithkline Beecham Corporation	Novel Compounds
UY29298A1 (es)	2004-12-23	2006-05-31	Glaxo Group Ltd	Compuestos
CA2590997A1 (en) *	2004-12-23	2006-07-06	Voyager Pharmaceutical Corporation	Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer`s disease
US7767710B2 (en) *	2005-05-25	2010-08-03	Calosyn Pharma, Inc.	Method for treating osteoarthritis
US20060269579A1 (en) *	2005-05-25	2006-11-30	Musculoskeletal Research Llc	Compositions for treating osteoarthritis
GB0512429D0 (en) *	2005-06-17	2005-07-27	Smithkline Beecham Corp	Novel compound
GB0704407D0 (en)	2007-03-07	2007-04-18	Glaxo Group Ltd	Compounds
US7943658B2 (en)	2007-07-23	2011-05-17	Bristol-Myers Squibb Company	Indole indane amide compounds useful as CB2 agonists and method
WO2009042854A1 (en) *	2007-09-26	2009-04-02	Musculoskeletal Research Llc	Ion-channel regulator compositions and methods of using same
UA103319C2 (en) *	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
GB0813142D0 (en)	2008-07-17	2008-08-27	Glaxo Group Ltd	Novel compounds
GB0813144D0 (en)	2008-07-17	2008-08-27	Glaxo Group Ltd	Novel compounds
WO2011012622A1 (en)	2009-07-30	2011-02-03	Glaxo Group Limited	Benzoxazinone derivatives for the treatment of glytl mediated disorders
WO2011023753A1 (en)	2009-08-27	2011-03-03	Glaxo Group Limited	Benzoxazine derivatives as glycine transport inhibitors
GB201000685D0 (en)	2010-01-15	2010-03-03	Glaxo Group Ltd	Novel compounds
GB201007791D0 (en)	2010-05-10	2010-06-23	Glaxo Group Ltd	Novel compounds
GB201007789D0 (en)	2010-05-10	2010-06-23	Glaxo Group Ltd	Novel Compound
US9115132B2 (en)	2010-07-09	2015-08-25	Convergence Pharmaceuticals Limited	Tetrazole compounds as calcium channel blockers
US8933132B2 (en)	2011-01-19	2015-01-13	Convergence Pharmaceuticals Limited	Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers
GB201122113D0 (en)	2011-12-22	2012-02-01	Convergence Pharmaceuticals	Novel compounds
GB201417497D0 (en)	2014-10-03	2014-11-19	Convergence Pharmaceuticals	Novel use
GB201417499D0 (en)	2014-10-03	2014-11-19	Convergence Pharmaceuticals	Novel use
GB201417500D0 (en)	2014-10-03	2014-11-19	Convergence Pharmaceuticals	Novel use
CN109906082A (zh)	2016-09-07	2019-06-18	塔夫茨大学信托人	使用免疫dash抑制剂和pge2拮抗剂的组合治疗
CA3209491A1 (en)	2021-03-15	2022-09-22	Saul Yedgar	Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease
CN115611901B (zh) *	2021-07-16	2024-04-30	华南理工大学	一种氮杂䓬类化合物或其药学上可接受的盐及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5002941A (en)	1985-12-12	1991-03-26	Smithkline Beecham Corporation	Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
US4925849A (en)	1987-06-15	1990-05-15	Fujisawa Pharmaceutical Company, Ltd.	Pharmaceutically useful pyrazolopyridines
US5155114A (en)	1989-01-23	1992-10-13	Fujisawa Pharmaceutical Company, Ltd.	Method of treatment using pyrazolopyridine compound
GB8901423D0 (en)	1989-01-23	1989-03-15	Fujisawa Pharmaceutical Co	Pyrazolopyridine compound and processes for preparation thereof
KR920702621A (ko)	1989-06-13	1992-10-06	스튜어트 알. 슈터	단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제
AU622330B2 (en)	1989-06-23	1992-04-02	Takeda Chemical Industries Ltd.	Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
IL95031A (en) *	1989-07-18	2007-03-08	Amgen Inc	Method for the production of a human recombinant tumor necrosis factor inhibitor
CA2084290A1 (en)	1990-06-12	1991-12-13	Jerry L. Adams	Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
GB9015764D0 (en)	1990-07-18	1990-09-05	Fujisawa Pharmaceutical Co	Pyrazolopyridine compound and processes for preparation thereof
FR2699077B1 (fr) *	1992-12-16	1995-01-13	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
US5300478A (en)	1993-01-28	1994-04-05	Zeneca Limited	Substituted fused pyrazolo compounds
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
AU1269495A (en)	1994-01-10	1995-08-01	Merck Frosst Canada Inc.	Phenyl heterocycles as cox-2 inhibitors
US5521213A (en) *	1994-08-29	1996-05-28	Merck Frosst Canada, Inc.	Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5552422A (en) *	1995-01-11	1996-09-03	Merck Frosst Canada, Inc.	Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
EA199700209A1 (ru) *	1995-04-04	1998-04-30	Глаксо Груп Лимитед	ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРИДИНА
US5700816A (en)	1995-06-12	1997-12-23	Isakson; Peter C.	Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
AU6111796A (en)	1995-06-12	1997-01-09	G.D. Searle & Co.	Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor
CA2224563A1 (en)	1995-06-12	1996-12-27	G.D. Searle & Co.	Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
GB9513508D0 (en) *	1995-07-03	1995-09-06	Fujisawa Pharmaceutical Co	Quinazoline derivatives
EA002775B1 (ru) *	1997-09-05	2002-08-29	Глаксо Груп Лимитед	ПРОИЗВОДНЫЕ 2,3-ДИАРИЛ-ПИРАЗОЛО[1,5-b]ПИРИДАЗИНОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ЦИКЛООКСИГЕНАЗЫ 2 (ЦОГ-2)
GB9919778D0 (en)	1999-08-21	1999-10-27	Zeneca Ltd	Chemical compounds

1998
- 1998-09-03 EA EA200000188A patent/EA002775B1/ru not_active IP Right Cessation
- 1998-09-03 KR KR10-2000-7002322A patent/KR100382619B1/ko not_active Expired - Fee Related
- 1998-09-03 ES ES98947502T patent/ES2203985T3/es not_active Expired - Lifetime
- 1998-09-03 AT AT03077298T patent/ATE281458T1/de not_active IP Right Cessation
- 1998-09-03 CA CA002303152A patent/CA2303152A1/en not_active Abandoned
- 1998-09-03 YU YU11900A patent/YU11900A/sh unknown
- 1998-09-03 DE DE69816651T patent/DE69816651T2/de not_active Expired - Lifetime
- 1998-09-03 TR TR2000/00595T patent/TR200000595T2/xx unknown
- 1998-09-03 DK DK98947502T patent/DK1032575T3/da active
- 1998-09-03 EP EP03077298A patent/EP1369421B1/de not_active Expired - Lifetime
- 1998-09-03 AT AT04025990T patent/ATE317845T1/de not_active IP Right Cessation
- 1998-09-03 BR BR9812046-8A patent/BR9812046A/pt not_active Application Discontinuation
- 1998-09-03 EE EEP200000113A patent/EE04617B1/xx not_active IP Right Cessation
- 1998-09-03 CN CNB988108763A patent/CN1155600C/zh not_active Expired - Fee Related
- 1998-09-03 HU HU0003644A patent/HUP0003644A3/hu unknown
- 1998-09-03 EP EP98947502A patent/EP1032575B1/de not_active Expired - Lifetime
- 1998-09-03 DE DE69827419T patent/DE69827419T2/de not_active Expired - Lifetime
- 1998-09-03 EP EP04025990A patent/EP1510519B1/de not_active Expired - Lifetime
- 1998-09-03 AT AT98947502T patent/ATE245649T1/de not_active IP Right Cessation
- 1998-09-03 HR HR960321A patent/HRP20000122B1/xx not_active IP Right Cessation
- 1998-09-03 SK SK294-2000A patent/SK283922B6/sk unknown
- 1998-09-03 ES ES04025990T patent/ES2256817T3/es not_active Expired - Lifetime
- 1998-09-03 DE DE69833464T patent/DE69833464T2/de not_active Expired - Lifetime
- 1998-09-03 PL PL98339059A patent/PL194557B1/pl unknown
- 1998-09-03 ES ES03077298T patent/ES2231757T3/es not_active Expired - Lifetime
- 1998-09-03 NZ NZ502985A patent/NZ502985A/en unknown
- 1998-09-03 AP APAP/P/2000/001753A patent/AP1354A/en active
- 1998-09-03 WO PCT/EP1998/005558 patent/WO1999012930A1/en not_active Application Discontinuation
- 1998-09-03 PT PT98947502T patent/PT1032575E/pt unknown
- 1998-09-03 US US09/508,029 patent/US6451794B1/en not_active Expired - Fee Related
- 1998-09-03 IL IL13468898A patent/IL134688A/xx not_active IP Right Cessation
- 1998-09-03 AU AU94395/98A patent/AU744997B2/en not_active Ceased
1999
- 1999-02-19 TW TW088102423A patent/TW570922B/zh not_active IP Right Cessation
2000
- 2000-02-25 IS IS5389A patent/IS5389A/is unknown
- 2000-03-03 NO NO20001102A patent/NO315559B1/no unknown
- 2000-03-28 BG BG104279A patent/BG64420B1/bg unknown
2002
- 2002-08-05 US US10/212,513 patent/US6861429B2/en not_active Expired - Fee Related
- 2002-08-05 US US10/212,514 patent/US6831097B2/en not_active Expired - Fee Related
2004
- 2004-10-27 US US10/974,893 patent/US20050113377A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ502985A (en)	2002-04-26
YU11900A (sh)	2002-11-15
EP1369421A1 (de)	2003-12-10
DE69816651T2 (de)	2004-04-01
EP1369421B1 (de)	2004-11-03
BG64420B1 (bg)	2005-01-31
SK2942000A3 (en)	2001-03-12
HUP0003644A3 (en)	2002-11-28
KR100382619B1 (ko)	2003-05-09
US6831097B2 (en)	2004-12-14
EA002775B1 (ru)	2002-08-29
WO1999012930A1 (en)	1999-03-18
US6451794B1 (en)	2002-09-17
AU9439598A (en)	1999-03-29
ATE317845T1 (de)	2006-03-15
TW570922B (en)	2004-01-11
HUP0003644A2 (hu)	2001-09-28
JP3167700B2 (de)	2001-05-21
ES2203985T3 (es)	2004-04-16
ES2231757T3 (es)	2005-05-16
US20030008872A1 (en)	2003-01-09
KR20010023669A (ko)	2001-03-26
US20050113377A1 (en)	2005-05-26
PL194557B1 (pl)	2007-06-29
HRP20000122A2 (en)	2001-02-28
IL134688A0 (en)	2001-04-30
CN1278263A (zh)	2000-12-27
IL134688A (en)	2005-05-17
NO315559B1 (no)	2003-09-22
HRP20000122B1 (en)	2003-06-30
ES2256817T3 (es)	2006-07-16
EA200000188A1 (ru)	2000-10-30
NO20001102L (no)	2000-05-03
DE69816651D1 (de)	2003-08-28
US20030040517A1 (en)	2003-02-27
EP1510519A1 (de)	2005-03-02
NO20001102D0 (no)	2000-03-03
CN1155600C (zh)	2004-06-30
PT1032575E (pt)	2003-11-28
DK1032575T3 (da)	2003-10-20
BG104279A (en)	2000-12-29
AP1354A (en)	2004-12-29
BR9812046A (pt)	2000-09-26
IS5389A (is)	2000-02-25
DE69833464T2 (de)	2006-08-24
EP1032575B1 (de)	2003-07-23
EP1032575A1 (de)	2000-09-06
DE69827419D1 (de)	2004-12-09
EE04617B1 (et)	2006-04-17
PL339059A1 (en)	2000-12-04
US6861429B2 (en)	2005-03-01
EP1510519B1 (de)	2006-02-15
JP2001515901A (ja)	2001-09-25
ATE281458T1 (de)	2004-11-15
EE200000113A (et)	2000-12-15
SK283922B6 (sk)	2004-05-04
AU744997B2 (en)	2002-03-07
DE69827419T2 (de)	2005-10-27
AP2000001753A0 (en)	2000-03-31
ATE245649T1 (de)	2003-08-15
CA2303152A1 (en)	1999-03-18
TR200000595T2 (tr)	2000-12-21

Publication	Publication Date	Title
DE69833464D1 (de)	2006-04-20	Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate
ATE222751T1 (de)	2002-09-15	Pharmazeutische aerosolzusammensetzung
DE69924999D1 (de)	2005-06-02	Lipasehemmer enthaltende pharmazeutische zusammensetzungen
DE122004000018I1 (de)	2004-09-30	4"-Substitutierte-9-Deoxo-9A-Aza-9A-Homoerythromycin a Derivate.
DE69726015D1 (de)	2003-12-11	Pharmazeutische zusammensetzung enthaltend koenzym q-10
DE69525148D1 (de)	2002-03-14	Pharmazeutische formulierung
DE59712959D1 (de)	2008-09-25	Orale pharmazeutische zubereitung enthaltend ibandronat
ID24654A (id)	2000-07-27	Formulasi farmasi omeprazola
EE200000383A (et)	2001-12-17	Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
ATE228823T1 (de)	2002-12-15	Pharmazeutische aerosolformulierung
DE69814091D1 (de)	2003-06-05	Voriconazol-enthaltende pharmazeutische zubereitungen
DE69940904D1 (de)	2009-07-02	Pharmazeutische zusammensetzung enthaltend epothilone
EE04294B1 (et)	2004-06-15	Farmatseutiline kompositsioon piperidinoalkanooldekongestandi kombineerimiseks
DE69809755D1 (de)	2003-01-09	Substituierte 1,2,3,4-tetrahydronaphthalin derivate
NO996372L (no)	2000-02-23	Fast farmasøytisk preparat inneholdende benzofuanderivater
PT966477E (pt)	2004-03-31	Derivados 3'-n-oxido, 3'-n-dimetilamina 9-oxima-eritromicina a
ATE432707T1 (de)	2009-06-15	Pharmazeutische zubereitung
EE9900545A (et)	2000-06-15	Farmatseutiline kompositsioon
DE59801987D1 (de)	2001-12-06	Pharmazeutische zusammensetzung enthaltend peptichemio
DE69614407D1 (de)	2001-09-13	Pharmazeutische zusammensetzungen
DE69830154D1 (de)	2005-06-16	Pharmazeutische zusammensetzungen
EE9900206A (et)	1999-12-15	N-sulfonüülindoliiniderivaate sisaldavad farmatseutilised kompositsioonid
DE69708130D1 (de)	2001-12-13	A-oxo-butansäuren enthaltende pharmazeutische zusammensetzung
ID25857A (id)	2000-11-09	Komposisi farmasi
EP1124557A4 (de)	2002-08-07	Pharmazeutische zusammensetzung

Legal Events

Date	Code	Title	Description
2007-03-15	8364	No opposition during term of opposition